Charles River Laboratories International CRL
NYSE CRL
$277.86 -3.81 (-1.35%)
As of: Sep 18, 2026 · 3:59 PM EDT

Charles River Laboratories International (CRL) Income from Non-Controlling Interests (2009 - 2026)

Charles River Laboratories International (CRL) posted Income from Non-Controlling Interests of $722000.0 for Q2 2026, up 1660.98% on a QoQ basis from $41000.0 in Q1 2026, and up 96.73% year-over-year from $367000.0 in Q2 2025.

Analysis

Charles River Laboratories International (CRL) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends

Charles River Laboratories International has reported Income from Non-Controlling Interests for 18 years, with the latest figure at $722000.0 in Q2 2026.

  • On a quarterly basis, Income from Non-Controlling Interests rose 96.73% year-over-year to $722000.0 in Q2 2026; TTM through Jun 2026 was $2.2 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $2.2 million, down 29.57% from the prior year.
  • Income from Non-Controlling Interests was $722000.0 for Q2 2026 at Charles River Laboratories International, up from $41000.0 in the prior quarter.
  • The five-year high for Income from Non-Controlling Interests was $2.4 million in Q3 2023, with the low at $41000.0 in Q1 2026.
  • Average Income from Non-Controlling Interests over 5 years is $1.0 million, with a median of $785500.0 recorded in 2023.
  • The sharpest annual moves came in 2024 and 2025: Income from Non-Controlling Interests slumped 92.57% in 2024, then soared 103.89% in 2025.
  • Over 5 years, Income from Non-Controlling Interests stood at $1.7 million in 2022, then advanced by 10.14% to $1.9 million in 2023, then plunged by 59.96% to $748000.0 in 2024, then sank by 64.57% to $265000.0 in 2025, then soared by 172.45% to $722000.0 in 2026.
  • The last three Income from Non-Controlling Interests figures came in at $722000.0 (Q2 2026), $41000.0 (Q1 2026), and $265000.0 (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Iqvia Holdings 44.72 Bn 42.64 Bn 1.44 Bn 2.00 Mn
2 Medpace Holdings 17.37 Bn 16.87 Bn 201.64 Mn -
3 Icon 13.65 Bn 12.72 Bn 479.29 Mn 19.44 Mn
4 Charles River Laboratories International 13.13 Bn 12.94 Bn 452.07 Mn 722,000.00
5 Fortrea Holdings 1.89 Bn 1.72 Bn 139.20 Mn -
6 Evotec SE 574.75 Mn 148.87 Mn - -
7 Ginkgo Bioworks Holdings 439.63 Mn 355.09 Mn 18.44 Mn -
8 Champions Oncology 69.43 Mn 65.03 Mn 7.70 Mn -
9 MindWalk Holdings 51.76 Mn 46.29 Mn 1.61 Mn -
10 VivoSim Labs 1.37 Mn 1.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 27, 2026 722,000.00
Mar 28, 2026 41,000.00
Dec 27, 2025 265,000.00
Sep 27, 2025 1.13 Mn
Jun 28, 2025 367,000.00
Mar 29, 2025 409,000.00
Dec 28, 2024 748,000.00
Sep 28, 2024 638,000.00
Jun 29, 2024 180,000.00
Mar 30, 2024 1.52 Mn
Dec 30, 2023 1.87 Mn
Sep 30, 2023 632,000.00
Jul 1, 2023 2.42 Mn
Apr 1, 2023 823,000.00
Dec 31, 2022 1.70 Mn
Sep 24, 2022 1.14 Mn
Jun 25, 2022 1.34 Mn
Mar 26, 2022 2.20 Mn
Dec 25, 2021 2.25 Mn
Sep 25, 2021 1.73 Mn